Today: 11 June 2026
Americas Gold and Silver Corporation stock (USAS) jumps as silver tops $100 — resale filing puts shares on watch
25 January 2026
2 mins read

Americas Gold and Silver Corporation stock (USAS) jumps as silver tops $100 — resale filing puts shares on watch

New York, Jan 25, 2026, 08:58 EST — Market closed

  • USAS closed Friday at $9.29, up 9.6%, then climbed to $9.47 in after-hours trading.
  • A new SEC prospectus allows a selling holder to unload 2.89 million shares tied to the Crescent Mine deal
  • Silver surging beyond $100 and the Fed’s January 28 decision stand out as critical challenges for the rally

Americas Gold and Silver Corporation shares climbed 9.6% to close at $9.29 on Friday, boosted by silver prices breaking past $100 an ounce. The momentum carried into after-hours trading, with the stock rising further to $9.47. Trading extended well beyond the usual 9:30 a.m. to 4:00 p.m. ET session.

A filing on Friday revealed a fresh update for next week. The company filed a prospectus to register 2.89 million shares for resale by Hale Capital Partners—about 0.9% of total shares outstanding—tied to the Crescent Mine acquisition. Americas made clear it isn’t selling any stock and won’t get any proceeds.

U.S. markets stayed shut on Sunday, giving investors time to weigh whether the metals rally will persist heading into Monday. The Federal Reserve’s policy meeting takes place Jan. 27-28, with a crucial rate decision slated for 2:00 p.m. ET and Chair Jerome Powell set to speak at 2:30 p.m. ET on the 28th.

Silver blasted through $100 an ounce on Friday, while gold soared to an all-time high of $4,988, Reuters reported. A surge in retail buying combined with tight supply pushed prices sharply higher. “Silver is in the midst of a self-propelled frenzy,” said StoneX analyst Rhona O’Connell. Still, BofA strategist Michael Widmer pegged a “fundamentally justified” silver price near $60. Reuters

News out of the Americas has fueled that leverage. On Jan. 21, the company updated its 2025 attributable silver production—meaning output adjusted for its ownership stake—at 2.65 million ounces, up 52% from 2024. It also announced its Cosalá operations in Mexico reached a record 1.19 million ounces for the year.

Chief executive Paul Andre Huet pointed to a “robust and rising silver price environment” as the driver behind higher output, saying it “amplifies” revenue and cash flow. The company also confirmed that its EC120 mine at Cosalá started commercial production on Jan. 1.

The release also revealed an unaudited consolidated cash balance of about $130 million as of Dec. 31, after a bought-deal private placement in December where underwriters bought shares outright. It noted antimony and copper by-product output from the Idaho-based Galena Complex—a point investors are starting to weigh again as Washington sharpens its focus on critical minerals.

Peers moved too, but the action was quieter. Hecla Mining closed Friday at $31.81, and Coeur Mining ended at $26.11, both boosted by the broader metals rally.

Monday kicks off with eyes on silver futures holding above $100, trying to avoid another steep plunge. USAS has behaved like a high-beta play on metals, while thin trading in small caps often magnifies these price moves.

Leverage cuts both ways. The resale registration means that stock could hit the market quickly if the holder decides to sell. Miners still expanding would likely take a big hit if silver prices plunge sharply.

Stock Market Today

  • Parabilis Medicines IPO Surges 58% on Nasdaq, Raises $670 Million
    June 10, 2026, 6:10 PM EDT. Parabilis Medicines (PBLS) soared 58% in its Nasdaq debut, closing at $31.60 against a $20 IPO price, after upsizing its offering to raise $670 million, surpassing expectations. The biopharma's shares opened strong, hitting a high of $34.02 amid high demand, with an additional $75 million from Regeneron in a private placement boosting total proceeds. Parabilis focuses on Helicon peptides targeting difficult protein sites, with a crucial Phase 3 tumor trial expected in early 2027. The IPO marks one of the largest venture-backed biotech offerings in 2026, signaling renewed investor interest and confidence in the biotech sector's health.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Cloud computing stocks face a packed week as Amazon job cuts loom and Fed meets
Previous Story

Cloud computing stocks face a packed week as Amazon job cuts loom and Fed meets

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday
Next Story

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday

Go toTop